GLP-1 is in every headline as a weight-loss drug. It is also a hormone your gut has made after every meal of your life. Evan Lynch on what it actually does.
Key Takeaways
GLP-1 is a hormone your body produces naturally with every meal. The prescription medications are engineered analogs of it, not simply manufactured copies of the same molecule.
It regulates appetite, blood sugar and how quickly your stomach empties.
GLP-1 medications (Ozempic, Wegovy, Mounjaro) mimic this natural hormone at higher, sustained levels.
Diet composition, including protein, fibre and healthy fats, influences how much GLP-1 your body releases naturally.
Understanding GLP-1 helps put weight-loss drug trends into honest context.
Evan Lynch is a CORU-registered dietitian with a BSc in Food Science and Health, a Postgraduate Diploma in Dietetics, and an MSc in Sports Nutrition. Evan is the Head of Nutrition for Europe at AG1, where he supports strategic nutrition direction, education, and evidence-based communication. Alongside this role, he runs a private practice supporting clients across sports nutrition, gastrointestinal disorders, geriatric nutrition, and weight management.
Over the past few years, "GLP-1" has become shorthand for a class of weight-loss medications. It's had a moment in the news, on social media and in conversations with friends and family. What tends to get lost in that conversation is that GLP-1, before any of that, is a hormone your own gut has been producing every time you eat, for your entire life. That being said, individual sensitivity to GLP-1 and capacity to synthesize it varies.
That's worth being precise about, because it's easy to state clumsily. GLP-1 the molecule can be, and has been, synthesised in a lab. The medications named after it are unambiguously drugs, prescribed and regulated as such. What's distinctive isn't that GLP-1 "can't be a drug", it's that the pathway these medications act on already exists in your body, running quietly in the background of digestion, whether or not you've ever heard of it. The medications are a separate, deliberately engineered product built to act on that existing pathway for far longer than the natural hormone does. They amplify a system that's already there. They don't invent a new one.
This article sets out what GLP-1 actually is, how it works in the body, how it relates to the medications named after it, and what the evidence says about supporting it through nutrition. No hype, no scare tactics, just the biology.
GLP-1 didn't arrive into an empty system. Hunger and fullness were already being regulated by a network of hormones and brain circuits long before this particular one made headlines, and understanding that network first makes it much easier to see where GLP-1 actually fits.
Leptin is produced by fat tissue itself, in rough proportion to how much of it you're carrying, and functions as a long-term signal of energy reserves rather than a meal-to-meal one. It travels to the hypothalamus and, broadly, tells the brain how well-stocked the body's energy stores are, supporting reduced appetite when reserves are ample. Leptin resistance, where the brain stops responding properly to this signal despite high circulating levels, is a well-documented feature of obesity, and part of why fat mass alone doesn't reliably predict how hungry someone feels.⊕
Ghrelin works in the opposite direction and is sometimes called the hunger hormone. It's produced mainly in the stomach, rises in the hours before a meal, and falls again once you've eaten, tracking hunger fairly closely across the day. Where leptin reflects long-term energy status, ghrelin behaves more like an active, moment-to-moment appetite signal, and the two are often described together as a push-pull pair.
GLP-1 stands for glucagon-like peptide-1. It's an incretin hormone, meaning it's released by the gut in response to food and helps regulate insulin. Specialised cells called L-cells, concentrated in the lining of your small intestine, release GLP-1 within minutes of eating, particularly in response to protein, fat and fibre.
Once released, GLP-1 travels through the bloodstream and acts in several places at once. It reaches the pancreas, where it prompts insulin release and dials down glucagon (a hormone that raises blood sugar). It acts on the stomach, slowing the rate at which food empties into the small intestine. And it reaches the brain, particularly the hypothalamus and brainstem, where it signals that you've eaten and are becoming full.
All of this happens as part of ordinary digestion. Every person with a functioning gut produces GLP-1 daily, regardless of whether they've ever taken a GLP-1 medication or supplement. It's one of several gut hormones, alongside others like PYY and CCK, that coordinate how your body responds to a meal.
GLP-1 also has a practical limitation that matters for understanding the medications built around it: it's broken down by an enzyme called DPP-4 within one to two minutes of release. That short half-life is precisely why pharmaceutical versions were engineered to resist this breakdown, which we'll come to shortly.
GLP-1's influence touches three connected systems.
Blood sugar. After a meal, GLP-1 helps the pancreas release insulin in a glucose-dependent way, meaning it ramps up insulin secretion mainly when blood sugar is elevated, rather than indiscriminately. It also suppresses glucagon, the hormone that would otherwise push glucose levels higher. Together, this helps prevent the sharp blood sugar swings that can follow a large or carbohydrate-heavy meal.
Gastric emptying. GLP-1 slows the rate at which food moves from the stomach into the small intestine. This has two effects: it smooths out the delivery of glucose into the bloodstream, and it extends the sensation of fullness after eating, since food remains in the stomach for longer.
Appetite signalling. GLP-1 acts directly on the same arcuate nucleus circuitry covered above, feeding into the POMC and AgRP neurons that integrate hunger and fullness signals.⊕ Research into the gut-brain axis has also identified GLP-1 activity in brain regions tied to food reward, which may help explain why elevated GLP-1 signalling is associated with reduced interest in highly palatable, calorie-dense foods, not just reduced hunger in a general sense, a reward-related effect that stands in interesting contrast to the endocannabinoid system's role in driving that same kind of eating.
This is the distinction that gets blurred most often, so it's worth being precise about it.
GLP-1 medications, including semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (marketed as Mounjaro, which also acts on a second gut hormone receptor called GIP), are prescription drugs engineered to mimic the natural hormone's effects. The key engineering problem they solve is that hormone's short half-life. Because natural GLP-1 is broken down within minutes, these medications are modified so they resist that breakdown and remain active in the body for days rather than minutes.
The practical result is that these medications produce a much higher and more sustained level of GLP-1 receptor activation than eating ever could on its own. That's a meaningful difference, not just a matter of degree. Natural, food-triggered GLP-1 release is a short-lived, self-limiting signal that rises and falls within an hour or two of a meal. A weekly injection of semaglutide keeps GLP-1 receptors engaged around the clock, which is why the medications can produce substantially larger and more sustained effects on appetite and blood sugar than diet alone.
So while the medications are named after the natural hormone and work through the same receptor, they aren't simply a concentrated version of what a high-protein breakfast does. They represent a different order of magnitude of receptor activation, which is also why they require medical supervision, come with , and are prescribed rather than sold over the counter.
GLP-1's journey from obscure gut hormone to household name took about four decades. Researchers had suspected since the early twentieth century that the gut released some kind of signal to the pancreas after eating, an idea known as the incretin effect, but it took until the 1980s for the specific hormone to be identified. By 1987, two research teams, including Joel Habener and Svetlana Mojsov, had confirmed that the active fragment of GLP-1 potently stimulated insulin release.⊕⊕
The obstacle that stood between that discovery and an actual medication was the hormone's fleeting half-life of roughly two minutes, far too short to be useful as a once-daily or once-weekly treatment. The breakthrough came from an unlikely source: in 1992, a researcher studying the venom of the Gila monster, a slow-moving desert lizard, identified a peptide called exendin-4 that activated the same receptor as GLP-1 but lasted for hours rather than minutes (Eng et al., 1992). That discovery led to exenatide, approved in 2005 as the first GLP-1 receptor agonist medication. Later medications, including liraglutide and semaglutide, were engineered directly from the human hormone rather than from venom, using chemical modifications to achieve the same resistance to rapid breakdown.
To a degree, yes, though it's important to be precise about what that means. Certain foods and eating patterns are well established in the research as natural triggers for GLP-1 release:
Protein is one of the strongest known dietary stimuli for GLP-1 secretion, which is part of why high-protein meals tend to be more filling than equivalent-calorie meals built around refined carbohydrates. Not all protein sources appear equal here. A controlled human trial found that co-ingesting whey protein hydrolysate with calcium-rich milk minerals raised postprandial GLP-1 to some of the highest physiological levels reported in the literature, an effect linked to dairy proteins' amino acid profile.⊕ That doesn't make plant protein a poor choice nutritionally, but it's a genuinely interesting, evidence-backed nuance if GLP-1 support specifically is what you're optimising for.
Soluble, viscous fibre (found in oats, psyllium, legumes and many vegetables) forms a gel-like substance in the digestive tract that slows digestion and has been shown in controlled trials to meaningfully change post-meal GLP-1 levels.
GLP-1 is not a new invention or a mysterious pharmaceutical compound. It's a gut hormone your body has always made, doing quiet, essential work every time you eat: helping regulate blood sugar, pacing digestion, and signalling fullness to your brain. The medications that share its name are a pharmaceutical amplification of that existing biological pathway, engineered to overcome the hormone's naturally short lifespan and sustain its effects for far longer than food ever could.
Understanding that distinction doesn't settle the separate question of whether a GLP-1 medication is right for any individual person; that's a conversation for a healthcare professional, based on individual health history and goals. But it does mean you can read the next GLP-1 headline with a clearer sense of what's actually being discussed: a hormone that's been part of your biology all along.
GLP-1 stands for glucagon-like peptide-1, a hormone produced by cells in your small intestine when you eat, especially in response to protein, fat and fibre. It travels through the bloodstream and to the brain, where it signals fullness, slows digestion, and helps regulate blood sugar by supporting insulin release. GLP-1 is entirely natural. Every person produces it daily, regardless of whether they use any GLP-1-related medication or supplement.
GLP-1 works along the gut-brain axis. After eating, it's released from the gut, prompting the pancreas to release insulin, slowing how quickly food leaves the stomach, and signalling the brain's appetite centres that you're full. This combination, steadier blood sugar, slower digestion and reduced hunger signalling, is why GLP-1 has become central to conversations about metabolism and weight management.
No. GLP-1 is the natural hormone; Ozempic, Wegovy and Mounjaro are medications designed to mimic or extend its effects at levels far beyond what the body produces on its own. The hormone itself is present in everyone, working in the background of digestion every day. The medications are a pharmaceutical amplification of that existing pathway, not a replacement for it.
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Journal of Biological Chemistry, 267(11), 7402–7405.
CCK (cholecystokinin) is closer to GLP-1 in character: a gut hormone released from the small intestine within minutes of eating, particularly in response to fat and protein. It signals to the brain via the vagus nerve rather than travelling there directly through the bloodstream, and its effects are short and meal-specific, slowing gastric emptying and helping bring a meal to a natural end. It also triggers the gallbladder to contract, which is where its name comes from.⊕
POMC and AgRP neurons, found in the arcuate nucleus of the hypothalamus, are less a hormone and more the control room where signals like leptin, ghrelin and others get integrated. POMC neurons release a molecule called alpha-MSH, which binds a receptor known as MC4R and suppresses appetite. A separate set of neurons releasing AgRP does the opposite, blocking that same receptor and driving hunger. The balance between these two neuron populations is central to appetite regulation, and disruptions to this specific pathway, including rare mutations in the MC4R gene itself, are among the most common known genetic causes of severe early-onset obesity.⊕
The endocannabinoid system works differently from everything above, in that its main effect runs toward increasing food intake rather than curbing it. The body's own cannabinoid-like molecules, principally anandamide and 2-arachidonoylglycerol (2-AG), act on CB1 receptors in the brain to promote eating, particularly of palatable, energy-dense food, and to reinforce the motivation to seek it out. It's the same receptor that THC acts on, which is why cannabis use is so reliably associated with increased appetite, the so-called munchies. Because of this appetite-driving effect, a CB1-blocking drug called rimonabant was developed and approved as an obesity treatment in Europe in the mid-2000s, but it was withdrawn a few years later after being linked to a meaningfully increased risk of depression and other psychiatric side effects, a useful reminder that appetite circuits are tightly interwoven with mood and reward, and that intervening in one rarely leaves the others untouched.⊕
Set against that backdrop, GLP-1 is a distinct voice in an already busy conversation: a gut hormone that acts quickly after eating and links digestion directly to the same hypothalamic circuitry that leptin, ghrelin and the melanocortin system all feed into. It isn't the whole system, and it isn't a new system. It's one well-understood, well-timed part of it, which is exactly what makes it worth explaining properly.
The combined effect, steadier blood sugar, slower digestion and reduced hunger signalling, is precisely why GLP-1 has become central to conversations about metabolism and weight management. It isn't a single on/off switch for appetite. It's one part of a broader hormonal conversation between your gut and your brain that happens after every meal.
It's also worth knowing that not every GLP-1 medication works through GLP-1 alone. Tirzepatide activates both the GLP-1 receptor and a second gut hormone receptor, for GIP (glucose-dependent insulinotropic polypeptide), which is thought to be part of why it has shown, on average, somewhat larger effects in trials than GLP-1-only medications. This dual-hormone approach is a reminder that appetite and blood sugar regulation involve more than one signalling pathway working together, GLP-1 is a major and well-understood piece of that system, but not the entire story.
It's a useful reminder that today's headlines are the visible tip of a research effort that's been running quietly for well over forty years, built on ordinary, incremental hormone biology rather than a sudden invention.
Healthy fats, eaten alongside other nutrients, also stimulate GLP-1 release, partly through fatty acid receptors in the gut lining.
Fermentable fibre feeding gut bacteria produces short-chain fatty acids, which independently support GLP-1 and PYY (another satiety hormone) release.
Eating patterns matter too. Eating slowly, keeping consistent meal timing, and avoiding highly processed, rapidly digested foods that spike and crash blood sugar all support more stable, effective GLP-1 signalling over the course of a day. Sleep also plays a supporting role. Poor or inconsistent sleep disrupts several appetite-related hormones at once, including leptin and ghrelin,⊕ and while GLP-1 itself is only one part of that picture, it's a good illustration of how interconnected hunger regulation really is, and why no single habit or nutrient works in isolation from the rest.
What this doesn't mean is that any food or supplement can replicate what a prescription GLP-1 medication does. The gap in scale is large, and no credible nutrition strategy closes it entirely. What good nutrition can do is support your body's own, natural GLP-1 response, which is a legitimate and worthwhile goal in its own right, separate from the weight-loss drug conversation entirely. We go deeper on the specific nutrients people are researching for this, including berberine, chromium and fibre, in a companion article on natural GLP-1 support.
Yes, to a degree. Eating more protein, fibre and healthy fats, slowing down meals, and keeping consistent eating patterns can all support your body's natural GLP-1 release. This won't replicate the effect of GLP-1 medications, but it's a legitimate, evidence-informed way to support satiety and metabolic health through nutrition. See our companion article on natural GLP-1 support for a deeper dive.
No, and it isn't even close. GLP-1 works alongside leptin (a long-term energy-status signal from fat tissue), ghrelin (a stomach hormone that rises before meals and drives hunger), CCK (a short-acting gut hormone released in response to fat and protein), and the POMC/AgRP neurons in the hypothalamus that integrate all of these signals. The endocannabinoid system adds a further layer, generally pushing in the opposite direction by promoting food intake rather than curbing it. GLP-1 is one well-understood, well-timed part of a much larger system, not the whole story.
This article is for general information only and isn't a substitute for personalised medical advice. Anyone considering a GLP-1 medication, or making significant changes to an existing treatment plan, should speak with a healthcare professional.
